Document Detail

Recombinant humanized anti-IL-2 receptor antibody (daclizumab) produces responses in patients with moderate aplastic anemia.
MedLine Citation:
PMID:  12881307     Owner:  NLM     Status:  MEDLINE    
In contrast to severe aplastic anemia (sAA), the appropriate management of patients with moderate pancytopenia is unclear. In this study, we examined the efficacy of a humanized monoclonal antibody recognizing interleukin-2 receptor (daclizumab), which has proven to be a successful immunosuppressive agent in solid organ and bone marrow transplantation. We treated 17 patients with moderate aplastic anemia (mAA) with 1 mg/kg every 2 weeks for 3 months. mAA was defined as depression of 2 of the 3 blood counts: absolute neutrophil count 1200/mm3 or less, platelet count 70,000/mm3 or less, hemoglobin level 8.5 g/dL or lower, and absolute reticulocyte count 60,000/mm3 or less. The primary end point of our protocol was a hematologic response in at least one affected peripheral blood value. Daclizumab had little toxicity. Six of the 16 (38%) evaluable patients responded to treatment. Two patients with previously chronic disease showed complete return of normal counts, which were sustained for more than 2 years following treatment. Four patients had single-lineage responses. Two previously transfusion-dependent patients became transfusion independent; one patient with many neutropenia-related infections had a normal neutrophil count following treatment. Daclizumab appears safe; its efficacy in this pilot protocol suggests that expanded study of this monoclonal antibody in immune-mediated bone marrow failure syndrome is warranted.
Jaroslaw P Maciejewski; Elaine M Sloand; Olga Nunez; Carol Boss; Neal S Young
Related Documents :
2308267 - Treatment of polycythemia vera by isovolemic large-volume erythrocytapheresis.
8481507 - Elevated interleukin-8 serum concentrations in beta-thalassemia and graft-versus-host d...
6730887 - Hyperpotassemia during massive blood transfusions.
19058587 - Growth velocity in transfusion dependent prepubertal thalassemia patients: results from...
24047677 - Atrioventricular valve regurgitation at diagnosis in single-ventricle patients: does it...
3690137 - Decreased bioactivity of circulating prolactin in patients with rheumatoid arthritis.
Publication Detail:
Type:  Clinical Trial; Journal Article     Date:  2003-07-24
Journal Detail:
Title:  Blood     Volume:  102     ISSN:  0006-4971     ISO Abbreviation:  Blood     Publication Date:  2003 Nov 
Date Detail:
Created Date:  2003-11-04     Completed Date:  2004-01-05     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  7603509     Medline TA:  Blood     Country:  United States    
Other Details:
Languages:  eng     Pagination:  3584-6     Citation Subset:  AIM; IM    
Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anemia, Aplastic / drug therapy*
Antibodies, Monoclonal / administration & dosage,  pharmacology*,  therapeutic use
Blood Cell Count
Immunoglobulin G / administration & dosage,  pharmacology*,  therapeutic use
Middle Aged
Pilot Projects
Receptors, Interleukin-2 / immunology
Recombinant Proteins / pharmacology,  therapeutic use
Time Factors
Treatment Outcome
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Immunoglobulin G; 0/Receptors, Interleukin-2; 0/Recombinant Proteins; 152923-56-3/daclizumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Transferrin receptor 1 is differentially required in lymphocyte development.
Next Document:  Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen c...